A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the ...

Reforming patent litigation to mirror successful outcomes across Europe could significantly accelerate US biosimilar market ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...